Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck

Showing 15 posts of 360 posts found.

1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

News

Merck elects Isabel De Paoli as CSO

September 27, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

Appointment

Merck elects Isabel De Paoli as CSO

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

News
images

Roche’s Ocrevus more effective than Merck’s Rebif, company claims

September 14, 2016
Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …

News
merck_and_co

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

News
merck_and_co

MSD drops osteoporosis trial drug due to stroke risk

September 5, 2016
Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke

MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …

News
merck_incweb

MSD joins Medivation race, says reports

August 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …

News
mr058666-web

Merck Q2 results beat analyst estimates

August 4, 2016
Medical Communications, Sales and Marketing Merck, financial results

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …

News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News
merckwindow

400 current and former employees join sexual discrimination lawsuit against MSD

July 25, 2016
Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …

News
merckwindow

MSD faces delay in C. diff drug approval as FDA requests more data

July 22, 2016
Medical Communications, Research and Development C diff, FDA, MSD, Merck

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …

News
msd

UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016
Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …

News
clinical_trial_3

Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer

July 6, 2016
Research and Development Merck, Pfizer, avelumab

Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …

News
mr058666-web

Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

July 4, 2016
Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …

News
merckincweb

MSD insulin glargine biosimilar meets primary endpoint in late-stage trials

June 14, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Merck, biosimilar, insulin, insuline glargine

MSD (NYSE: MRK), known as Merck in the US and Canada, has announced results from two Phase III studies evaluating …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024